Glibclay M 500 Tablet combines Glibenclamide 5mg and Metformin 500mg, providing a balanced dual-action approach for managing type-2 diabetes mellitus. It is prescribed for patients who require combination therapy to achieve optimal glycemic control.
Glibenclamide stimulates pancreatic insulin secretion, while Metformin enhances insulin sensitivity and reduces hepatic glucose output. Together, they offer effective control over fasting and postprandial blood sugar levels.
This combination is ideal for patients who do not achieve target glucose levels with monotherapy and ensures long-term metabolic stability. Its oral administration and favorable tolerability profile support adherence and consistent therapy outcomes.
Adding Glibclay M 500 Tablet to your diabetes and metabolic-care portfolio strengthens your offerings in chronic care management, unlocking opportunities in hospital supply, retail pharmacy distribution, institutional procurement, export markets, and third-party manufacturing. Its high prescription rate ensures continuous demand and strong commercial performance.